Drug Price Trends for NDC 81520-0250

Average Pharmacy Cost for 81520-0250

Drug Name	NDC	Price/Unit ($)	Unit	Date
VOQUEZNA DUAL PAK	81520-0250-01	7.30359	EACH	2025-01-22
VOQUEZNA DUAL PAK	81520-0250-14	7.30359	EACH	2025-01-22

Best Wholesale Price for NDC 81520-0250

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for VOQUEZNA DUAL PAK (NDC: 81520-0250)

The pharmaceutical landscape is constantly evolving, with new drugs entering the market to address unmet medical needs. One such medication that has garnered attention is VOQUEZNA DUAL PAK, identified by the National Drug Code (NDC) 81520-0250. This article delves into a comprehensive market analysis and price projections for this innovative drug, offering valuable insights for healthcare professionals, investors, and industry analysts.

Understanding VOQUEZNA DUAL PAK

VOQUEZNA DUAL PAK is a combination medication designed to treat Helicobacter pylori (H. pylori) infection, a common bacterial infection that can lead to various gastrointestinal issues. The drug consists of two components: vonoprazan fumarate and amoxicillin[4].

Composition and Dosage

The VOQUEZNA DUAL PAK contains:

• Vonoprazan Tablets, 20 mg: pale red, oval, film-coated tablets
• Amoxicillin Capsules, 500 mg: yellow, opaque, hard gelatin capsules

The recommended dosage is vonoprazan 20 mg twice daily plus amoxicillin 1,000 mg three times a day, with or without food, for 14 days[4].

Market Positioning and Competitive Landscape

VOQUEZNA DUAL PAK enters a market dominated by proton pump inhibitors (PPIs) and antibiotics. However, its unique formulation and potential advantages position it as a disruptive force in the treatment of acid-related disorders.

Vonoprazan has been highly successful in Japan, achieving ~$850M annual net sales and gaining significant market share predominantly driven by volumetric gains from generic competitors[6].

This success in the Japanese market serves as a promising indicator for the drug's potential in other regions, including the United States.

Market Size and Growth Potential

The Vonoprazan Fumarate API Market is projected to reach USD 4.83 Billion by 2034, growing at a CAGR of 14.51%[5]. This substantial growth forecast underscores the significant market opportunity for VOQUEZNA DUAL PAK and similar medications.

Pricing Analysis

Understanding the pricing dynamics of VOQUEZNA DUAL PAK is crucial for both healthcare providers and patients. Let's examine the current pricing trends and future projections.

Current Pricing

As of January 1, 2025, the price per unit for VOQUEZNA TRIPLE PAK (NDC 81520-0255) is $7.27053[1]. While this data is for the triple pack version, it provides a baseline for understanding the pricing strategy for the DUAL PAK.

Price Fluctuations

Historical data shows slight price fluctuations:

• January 1, 2025: $7.27053 per unit
• December 18, 2024: $6.92432 per unit
• November 20, 2024: $6.91930 per unit[1]

These fluctuations, while minor, indicate a dynamic pricing environment that responds to market forces and production costs.

Factors Influencing Price Projections

Several factors will influence the future pricing of VOQUEZNA DUAL PAK:

1. Research and Development Costs

The high costs associated with drug development and clinical trials are often reflected in the final pricing of new medications. As vonoprazan fumarate is a relatively new compound, these costs may continue to impact pricing in the near term.

2. Manufacturing Expenses

The production of vonoprazan fumarate API involves complex processes, which can affect the overall cost structure. Any improvements in manufacturing efficiency could potentially lead to price reductions over time.

3. Market Demand

As awareness of H. pylori infection and its complications grows, demand for effective treatments like VOQUEZNA DUAL PAK may increase, potentially supporting higher prices.

4. Competition

The presence of established PPIs and potential future entrants in the market could exert downward pressure on pricing.

5. Regulatory Environment

Changes in healthcare policies or drug pricing regulations could significantly impact the pricing strategy for VOQUEZNA DUAL PAK.

Market Drivers and Opportunities

Several factors are driving the growth of the vonoprazan fumarate API market, which directly impacts VOQUEZNA DUAL PAK:

1. Increasing prevalence of gastrointestinal disorders
2. Growing healthcare expenditure, particularly in emerging economies
3. Favorable regulatory approvals
4. Expanding global pharmaceutical industry
5. High efficacy and patient compliance compared to traditional PPIs
6. Strategic collaborations and partnerships in the industry
7. Rising awareness and diagnosis of acid-related disorders
8. Market expansion in emerging economies[3]

These drivers present significant opportunities for VOQUEZNA DUAL PAK to capture market share and potentially justify premium pricing.

Market Challenges and Restraints

Despite the promising outlook, several challenges could impact the market performance and pricing of VOQUEZNA DUAL PAK:

1. High development and production costs
2. Stringent regulatory requirements
3. Intellectual property challenges
4. Potential adverse effects and safety concerns
5. Limited awareness in developing regions
6. Competition from alternative therapies
7. Economic instability in certain markets
8. Supply chain disruptions
9. Market penetration challenges[3]

Addressing these challenges will be crucial for maintaining competitive pricing while ensuring profitability.

Future Price Projections

While specific long-term price projections are challenging to make due to the dynamic nature of the pharmaceutical market, several trends can be anticipated:

Short-term Outlook (1-2 years)

Prices are likely to remain relatively stable, with potential small increases to account for inflation and ongoing R&D costs. The current price range of $6.90 to $7.30 per unit may serve as a baseline.

Medium-term Outlook (3-5 years)

As market penetration increases and manufacturing processes are optimized, there may be room for modest price reductions. However, this could be offset by increased demand and expanded indications.

Long-term Outlook (5+ years)

The long-term pricing strategy will largely depend on the drug's efficacy data, market position, and competitive landscape. If VOQUEZNA DUAL PAK establishes itself as a superior treatment option, it may command premium pricing. Conversely, increased competition or patent expiration could lead to price decreases.

Market Segmentation and Targeting

Understanding the market segmentation for VOQUEZNA DUAL PAK is crucial for developing effective pricing strategies:

By Application

• Gastroesophageal Reflux Disease (GERD)
• Peptic Ulcer Disease
• Helicobacter pylori Infection
• Non-Erosive Reflux Disease (NERD)[3]

By Route of Administration

• Oral
• Intravenous
• Subcutaneous[5]

By Type

• Generic
• Branded[5]

Targeting specific segments with tailored pricing strategies could maximize market penetration and revenue generation.

Comparative Analysis with Competitors

To fully understand the pricing potential of VOQUEZNA DUAL PAK, it's essential to compare it with existing treatments:

1. Proton Pump Inhibitors (PPIs): Generally lower-priced due to generic availability, but may be less effective in certain patient populations.

2. H2 Receptor Antagonists: Often available over-the-counter at lower prices, but typically less potent than PPIs or VOQUEZNA DUAL PAK.

3. Antibiotic Combinations: Pricing varies widely depending on the specific antibiotics used and their patent status.

VOQUEZNA DUAL PAK's unique formulation and potential for improved efficacy may justify a price premium over these alternatives, particularly for patients who have not responded well to traditional treatments.

Global Market Expansion and Pricing Implications

As VOQUEZNA DUAL PAK expands into new markets, pricing strategies may need to be adjusted to account for:

• Local healthcare systems and reimbursement policies
• Economic conditions in target markets
• Regional competition and treatment preferences
• Regulatory requirements and approval timelines

A flexible, market-specific pricing approach will be crucial for maximizing global market penetration and revenue generation.

Impact of Clinical Data on Pricing

Ongoing clinical trials and real-world evidence will play a significant role in shaping the future pricing of VOQUEZNA DUAL PAK. Positive outcomes demonstrating superior efficacy or safety profiles compared to existing treatments could support premium pricing and increased market share.

The PHALCON-NERD-301 Phase 3 trial met its primary endpoint, with vonoprazan showing significant improvement in heartburn-free days compared to placebo[6].

Such clinical successes strengthen the value proposition of VOQUEZNA DUAL PAK and may justify higher pricing in the future.

Reimbursement Landscape and Pricing Implications

The reimbursement landscape for VOQUEZNA DUAL PAK will significantly impact its market access and pricing strategy. Factors to consider include:

• Coverage decisions by public and private payers
• Placement on formularies and tier status
• Prior authorization requirements
• Patient copay and coinsurance levels

Securing favorable reimbursement terms will be crucial for maintaining competitive pricing while ensuring patient access.

Key Takeaways

1. VOQUEZNA DUAL PAK represents a significant advancement in the treatment of H. pylori infection and acid-related disorders.

2. Current pricing for the related VOQUEZNA TRIPLE PAK ranges from $6.91 to $7.27 per unit, providing a baseline for DUAL PAK pricing.

3. The Vonoprazan Fumarate API Market is projected to reach USD 4.83 Billion by 2034, indicating substantial growth potential.

4. Factors influencing future pricing include R&D costs, manufacturing expenses, market demand, competition, and regulatory environment.

5. Market drivers such as increasing prevalence of gastrointestinal disorders and favorable regulatory approvals support potential premium pricing.

6. Challenges including high development costs and competition from alternative therapies may exert downward pressure on pricing.

7. Future price projections suggest stability in the short term, with potential for modest reductions or premium positioning in the long term, depending on market performance and clinical data.

8. Global market expansion and reimbursement landscape will play crucial roles in shaping pricing strategies across different regions.

9. Positive clinical trial outcomes, such as the PHALCON-NERD-301 results, strengthen the value proposition and may support higher pricing.

10. A flexible, market-specific pricing approach will be essential for maximizing global market penetration and revenue generation.

FAQs

1. Q: How does VOQUEZNA DUAL PAK differ from traditional PPIs? A: VOQUEZNA DUAL PAK contains vonoprazan, a potassium-competitive acid blocker (PCAB), which offers potentially faster onset and longer duration of action compared to traditional PPIs.

2. Q: Will VOQUEZNA DUAL PAK be covered by insurance? A: Coverage will vary by insurer and plan. As a new medication, it may require prior authorization or have higher copays initially. Patients should check with their insurance providers for specific coverage details.

3. Q: How might the pricing of VOQUEZNA DUAL PAK affect patient access? A: The pricing strategy will aim to balance profitability with patient access. Manufacturer assistance programs and negotiations with payers may help improve affordability for patients.

4. Q: What factors could lead to price decreases for VOQUEZNA DUAL PAK in the future? A: Potential factors include increased competition, patent expiration, improved manufacturing efficiency, and pressure from payers and regulators to reduce healthcare costs.

5. Q: How does the U.S. market potential for VOQUEZNA DUAL PAK compare to its success in Japan? A: While the U.S. market presents a significant opportunity, factors such as different healthcare systems, competition, and regulatory environments may impact its performance compared to Japan. However, the drug's success in Japan serves as a positive indicator for its potential in the U.S. market.

Sources cited: [1] https://www.drugpatentwatch.com/p/drug-price/ndc/81520-0255 [3] https://www.verifiedmarketresearch.com/product/vonoprazan-fumarate-api-market/ [4] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 [5] https://www.marketresearchfuture.com/reports/vonoprazan-fumarate-api-market-30898 [6] https://investors.phathompharma.com/static-files/b0ed3436-8522-4afb-a8b8-e4f66f2ec63d

Last updated: 2025-02-03